New York A07409 expands the definition of opioid antagonists to include all FDA-approved forms and doses of Naloxone.

New York A07409 amends the public health law, mental hygiene law, education law, and insurance law to redefine "opioid antagonist" to include all FDA-approved forms and doses of Naloxone. The Department of Health must approve all FDA-approved forms and doses of Naloxone as opioid antagonists and make them available. The bill also mandates training for law enforcement and first responders on opioid antagonist use and prohibits insurers from discriminating against individuals prescribed opioid antagonists.

New York A07409 expands the definition of opioid antagonists to include all FDA-approved forms and doses of Naloxone.

New York A07409 amends the public health law, mental hygiene law, education law, and insurance law to redefine "opioid antagonist" to include all FDA-approved forms and doses of Naloxone. The Department of Health must approve all FDA-approved forms and doses of Naloxone as opioid antagonists and make them available. The bill also mandates training for law enforcement and first responders on opioid antagonist use and prohibits insurers from discriminating against individuals prescribed opioid antagonists.